Blog
RSS FeedPosted by Michael Wonder on 20 Nov 2023
Landmark medicines deal to boost nation’s health, save NHS £14 billion, and support research investment
20 November 2023 - Pro-innovation and pro-competition agreement will introduce a new mechanism to support lower industry payment rates for more ...
Posted by Michael Wonder on 13 Apr 2023
‘A global outlier’: how drug firms are fighting back against UK tax increases
13 April 2023 - With the UK tax on net sales of branded medicines quadrupling over the past three years, medicine ...
Posted by Michael Wonder on 01 Mar 2023
ABPI sets out new proposals to support the NHS and economic growth
1 March 2023 - The pharmaceutical industry’s offer includes an annual £1 billion boost to the NHS as well as an ...
Posted by Michael Wonder on 17 Feb 2023
High drug prices are not justified by industry’s spending on research and development
15 February 2023 - Aris Angelis and colleagues argue that by refocusing their spending drug companies could provide more innovative ...
Posted by Michael Wonder on 07 Feb 2023
The EU butts heads with big pharma to make medicines cheaper
2 February 2023 - The bloc’s pharma reform aims to get new drugs to patients faster, for less money. But it ...
Posted by Michael Wonder on 06 Feb 2023
Pharma industry urges halt to further rises in record revenue clawbacks
2 February 2023 - The pharmaceutical industry is calling on the government to scrap plans to raise the statutory revenue clawback ...
Posted by Michael Wonder on 19 Jan 2023
The battle over European drug pricing
19 January 2023 - UK and EU must balance health cost control with plans to grow life sciences. ...
Posted by Michael Wonder on 17 Jan 2023
Bayer shifts pharma focus away from ‘innovation unfriendly’ Europe
16 January 2023 - Bayer has said it is shifting the focus of its pharmaceutical business to the US and ...
Posted by Michael Wonder on 16 Jan 2023
AbbVie and Eli Lilly, two of the world’s largest pharmaceutical companies, have sent a warning signal to the UK government by leaving the voluntary medicines pricing agreement in protest over increasingly punitive revenue clawbacks
16 January 2023 - AbbVie and Lilly have left the UK’s Voluntary Scheme for Branded Medicines Pricing and Access, a ...
Posted by Michael Wonder on 18 Mar 2022
Update to the statutory scheme to control the costs of branded health service medicines
15 March 2022 - The UK Government is seeking views on its proposal to increase the rate of payments made ...
Posted by Michael Wonder on 16 Apr 2020
Aid groups ask UK gov to stop pharma 'profiteering' from COVID-19
16 April 2020 - As of this morning – Thursday April 16 – the current recorded case count for COVID-19 ...
Posted by Michael Wonder on 07 Mar 2020
Is it time to nationalise the pharmaceutical industry?
4 March 2020 - Drug companies fail to take account of the public interest and relentlessly focus on short term returns, ...
Posted by Michael Wonder on 17 Jan 2020
Pricing of pharmaceuticals is becoming a major challenge for health systems
13 January 2020 - Manufacturers using their market power to maximise profits results in prices that are unjustifiable and unaffordable. ...
Posted by Michael Wonder on 10 Dec 2019
Biotech companies defend prices of one-off gene therapy
9 December 2019 - Latest treatments with price tags as high as $2 million require new financing models. ...
Posted by Michael Wonder on 07 Dec 2019
US pharma companies really do want Britain to pay more for drugs
6 December 2019 - When President Donald Trump arrived in the United Kingdom this week, he landed bang in the ...